Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
-0.44 (-1.26%)
Real-time:   10:11AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 34.50 - 35.35
52 week 27.51 - 40.87
Open 35.19
Vol / Avg. 29,689.00/477,054.00
Mkt cap 1.44B
P/E 89.08
Div/yield     -
EPS 0.39
Shares 41.31M
Beta 1.13
Inst. own 100%
May 6, 2014
Q1 2014 Acorda Therapeutics, Inc. Earnings Release (Tentative) Add to calendar
Mar 3, 2014
Acorda Therapeutics, Inc. at Cowen Health Care Conference
Feb 26, 2014
Acorda Therapeutics, Inc. at RBC Capital Markets Healthcare Conference
Feb 25, 2014
Acorda Therapeutics, Inc. at Citi Global Healthcare Conference
Feb 13, 2014
Acorda Therapeutics, Inc. at Leerink Swann Global Healthcare Conference
Feb 13, 2014
Q4 2013 Acorda Therapeutics, Inc. Earnings Release
Feb 13, 2014
Q4 2013 Acorda Therapeutics, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 6.69% 4.89%
Operating margin 13.77% 9.03%
EBITD margin - 11.11%
Return on average assets 4.16% 2.80%
Return on average equity 5.73% 3.98%
Employees 378 -
CDP Score - -


420 Saw Mill River Road
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Lauren M. Sabella Executive Vice President - Commercial Development
Age: 52
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 56
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 55
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 49
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
John P. Kelley Independent Director
Age: 60
Bio & Compensation  - Reuters